Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Oral hepatitis B vaccine could become a reality

In a new study, researchers report progress toward perfecting a radical new method of producing vaccines using genetically modified corn. The approach could lead to an oral hepatitis B vaccine that requires no refrigeration and costs less than $1 per dose to manufacture.

Published
17 hours ago
From
Medical Xpress
Cipla announces the launch of generic drug Sofosbuvir in India under the brand name ‘Hepcvir`

Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, Cipla is now all set to make the drug Sofosbuvir available to Indian patients in a week’s time. The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries.

Published
31 March 2015
From
Cipla press release
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C

Primarily due to HCV, Japan has one of the highest rates of liver cancer of any industrialized country. Of the more than one million people chronically infected with HCV, 20-30 percent have the genotype 2 strain of the virus.

Published
31 March 2015
From
Gilead press release
HCV sexual transmission linked to anal sex, drug use, lower CD4 count

In addition to the usual risk factors for hepatitis C virus (HCV) sexual transmission seen in most previous studies – such as anal sex and having other

Published
31 March 2015
By
Liz Highleyman
World first trials for hepatitis C wonder drug in Sydney's maximum security jails

Two of NSW's maximum security jails are the location for a world-first trial of a new wonder drug that could stop the spread of the blood-borne disease hepatitis C through the prison populations.

Published
30 March 2015
From
Sydney Morning Herald
KEI Europe asks Romanian government to issue compulsory licences on hepatitis C medicines

For a country with a gross national income (GNI) per capita of $9,060, roughly one-quarter of the overall GNI per capita across the EU, the medicines are simply too costly to be within reach of patients in need, and put strains on the government's ability to provide reimbursements.

Published
23 March 2015
From
Knowledge Ecology International
Indian generic companies should reject Gilead’s controversial hepatitis C ‘Anti-Diversion’ programme

Ahead of a meeting in Jaipur, India next week between US pharmaceutical company Gilead Sciences and several Indian companies which have entered into an agreement with Gilead to produce hepatitis C drugs, Médecins Sans Frontières/Doctors Without Borders (MSF) urged the generic companies to reject a highly-controversial programme that could compromise people’s treatment and confidentiality.

Published
19 March 2015
From
MSF
Gilead to require proof of citizenship to buy Sovaldi in poor countries

Médecins Sans Frontières/Doctors Without Borders (MSF) is urging Gilead to drop some of the provisions. If Gilead won't, MSF suggests that generic drugmakers ignore some of the requirements, like demanding that patients provide proof of citizenship to fill a prescription.

Published
19 March 2015
From
Fierce Pharma
Bristol-Myers Squibb Co. Is Back in the Hepatitis C Race

Bristol-Myers Squibb took an intriguing approach to developing its hepatitis C drug, daclatasvir. Rather than focus its trials on the United States, the globe's biggest market for spending on medicine, it concentrated trials on Japan. That move allowed daclatasvir to carve out an early lead in Japan, but it also left investors wondering what the company's strategy for the drug in the United States would be -- particularly after the FDA balked at an initial application to approve the drug last fall. This week, Bristol-Myers shed some light on its strategy by announcing that it's resubmitting daclatasvir for approval in the U.S. as an adjunct treatment to be used alongside Gilead Sciences' (NASDAQ: GILD ) top-selling HCV drug Sovaldi in genotype 3 patients.

Published
18 March 2015
From
Motley Fool
Hepatitis C Drugs Will 'Strain Budgets': Study

New hepatitis C drugs promise cure rates above 90 percent, but could prove to be budget-busters for public and private health insurers, a new analysis finds.

Published
17 March 2015
From
WebMD
← First12345...161Next →

Filter by country